(2S)-methyl 2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate | 1378912-69-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-methyl 2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
• 英文别名: methyl (2S)-2-[[[(4R,5R,6R,8R)-8-(2,4-dioxopyrimidin-1-yl)-5-hydroxy-3,7-dioxaspiro[3.4]octan-6-yl]methoxy-phenoxy-phosphoryl]amino]propanoate；methyl (2S)-2-[[[(4R,5R,6R,8R)-8-(2,4-dioxopyrimidin-1-yl)-5-hydroxy-1,7-dioxaspiro[3.4]octan-6-yl]methoxy-phenoxyphosphoryl]amino]propanoate
• CAS: 1378912-69-6
• 化学式: C₂₁H₂₆N₃O₁₀P
• 分子量: 511.425
• InChiKey: WRQBUEICDFSJKX-LHGNKGQLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  35
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  162
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  1-((6aR,8R,9R,9aR)-2,2,4,4-tetraisopropyldihydro-6H,8H-spiro[furo[3,2-f ][1,3,5,2,4]trioxadisilocine-9,2′-oxetan]-8-yl)pyrimidine-2,4(1H,3H)-dione 在 N-甲基咪唑 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (2S)-methyl 2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxaspiro[3.4]octan-7-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
  参考文献：
  名称：

  Use of 2′-Spirocyclic Ethers in HCV Nucleoside Design

  摘要：

  Conformationally restricted 2'-spironucleosides and their prodrugs were synthesized as potential anti-HCV agents. Although the replicon activity of the new agents containing pyrimidine bases was modest, the triphosphate of a 2'-oxetane cytidine analogue demonstrated potent intrinsic biochemical activity against the NS5B polymerase, with IC50 = 8.48 mu M. Activity against NS5B bearing the S282T mutation was reduced. Phosphoramidate prodrugs of a 2'-oxetane 2-amino-6-O-methylpurine nucleoside demonstrated potent anti-HCV activity in vitro, and the corresponding triphosphate retained similar potent activity against both wild-type and S282T HCV NS5B polymerase.

  DOI：

  10.1021/jm401224y

文献信息

• COMPOUNDS
  申请人：DU JINFA

  公开号：US20120142626A1

  公开（公告）日：2012-06-07

  Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus.

  本文公开了2'-螺环核苷及其衍生物，用于治疗感染丙型肝炎病毒或登革热病毒的患者。
• 2'-SPIRO-NUCLEOSIDES FOR USE IN THE THERAPY OF HEPATITIS C
  申请人：Gilead Pharmasset LLC

  公开号：EP3042910B1

  公开（公告）日：2019-01-09
• US8841275B2
  申请人：——

  公开号：US8841275B2

  公开（公告）日：2014-09-23
• US9394331B2
  申请人：——

  公开号：US9394331B2

  公开（公告）日：2016-07-19
• Use of 2′-Spirocyclic Ethers in HCV Nucleoside Design
  作者：Jinfa Du、Byoung-Kwon Chun、Ralph T. Mosley、Shalini Bansal、Haiying Bao、Christine Espiritu、Angela M. Lam、Eisuke Murakami、Congrong Niu、Holly M. Micolochick Steuer、Phillip A. Furman、Michael J. Sofia

  DOI：10.1021/jm401224y

  日期：2014.3.13

  Conformationally restricted 2'-spironucleosides and their prodrugs were synthesized as potential anti-HCV agents. Although the replicon activity of the new agents containing pyrimidine bases was modest, the triphosphate of a 2'-oxetane cytidine analogue demonstrated potent intrinsic biochemical activity against the NS5B polymerase, with IC50 = 8.48 mu M. Activity against NS5B bearing the S282T mutation was reduced. Phosphoramidate prodrugs of a 2'-oxetane 2-amino-6-O-methylpurine nucleoside demonstrated potent anti-HCV activity in vitro, and the corresponding triphosphate retained similar potent activity against both wild-type and S282T HCV NS5B polymerase.